David N. Cooper is Professor of Human Molecular Genetics at Cardiff University. He obtained his PhD in molecular biology from Edinburgh University in 1983. Having worked on the molecular genetics of inherited disorders of thrombosis and haemostasis at the University of London, he took up his present position in 1995. His research interests are largely focused upon elucidating the mechanisms of mutagenesis underlying human genetic disease, but include genotype-phenotype relationships in various inherited conditions, as well as human evolutionary and population genetics. He has published over 450 papers in the field of human molecular genetics and has co-authored or co-edited a number of books including Human Gene Mutation (1993), Nature Encyclopedia of the Human Genome (2003), Molecular Genetics of Lung Cancer (2005), Handbook of Human Molecular Evolution (2008) and Copy Number Variation and Disease (2009). He curates the Human Gene Mutation Database (http://www.hgmd.org), a comprehensive database of mutations causing human inherited disease, which is marketed internationally through a commercial partner, BIOBASE GmbH.
Mechanisms of mutagenesis; genotype-phenotype relationship; human evolutionary; population genetics
Dr. William Cho is a Biomedical Scientist in Queen Elizabeth Hospital. His main research interests have been focusing on cancer studies utilizing high-throughput technologies to discover biomarkers for cancer diagnosis, treatment prediction and prognostication. He is a Chartered Scientist granted by the Science Council (UK), a Registered Chinese Medicine Practitioner (HK), and Guest Professor of a number of Universities and a Fellow Member of several institutes, including the Institute of Biomedical Science (UK), Hong Kong Institute of Biomedical Science and Hong Kong Society for Molecular Diagnostic Sciences. Dr. Cho has published over 200 peer-reviewed papers (Lancet Oncology, Clinical Cancer Research, Clinical Chemistry, Annual Oncology, etc) covering cancer biomarkers, proteomics, microRNAs, Chinese medicine and plenty of books including "MicroRNAs in cancer translational research", "An omics perspective on cancer research", "Supportive cancer care with Chinese medicine", etc.
He serves as the editor-in-chief, editor and associate editor of a number of international medical journals. Dr Cho is also an international renowned grant reviewer of the Hope Funds for Cancer Research (USA), Cancer Research (UK), MRC Research Grant (UK), Health Research Board (Ireland), Science Foundation (Ireland), Istituto Toscano Tumori (Firenze), The Foundation Fournier-Majoie for Innovation (Brussels), National Medical Research Council (Singapore), The Medical Research Council (South Africa), and Academia Sinica Investigator Award (Taiwan), etc.
Cancer biomarker; microRNA; proteomics
Dr. Ramón Cacabelos is Professor and Chair of Genomic Medicine at Camilo José Cela University, Madrid, Spain. And President of the EuroEspes Biomedical Research Center, Corunna, Spain. He received his Ph.D. from Santiago University. He has published over 600 papers and 24 books, and is Editor-in-Chief of the first World Guide for Drug Use and Pharmacogenomics and President of the World Association of Genomic Medicine. He is also serving as the editorial board member and Editor-in-Chief of many international journals.
Neurodegenerative; disorders; genomics of brain disorders; neurogenetics; drug development for CNS disorders and dementia; epigenomics; pharmacogenomics of CNS disorders and pementia
Andrea was born in Procida, a little island in the bay of Naples, Italy. After graduating from the high school in Ischia he moved to Naples to study Molecular Biology at the University of Naples Federico II. For his Bachelor degree he worked at the Italian National Cancer Institute under the supervision of Prof. Nicola Normanno. He received his MSc degree in Molecular Biology (summa cum laude) in 2002. Subsequently, he joined Prof. Maurizio D’Esposito’s group at Institute of Genetics and Biophysics (IGB-National Council of Research, CNR), Naples, studying the role of chromatin and DNA modifications in cancer-and this was the time when his interest in epigenetics began. He decided to stay in D’Esposito’s lab to do his PhD, focusing on the epigenetic mechanism of SPRY3 gene silencing in humans.
As a part of his Doctoral training Andrea came to Neil Brockdorff’s lab in 2006 as a visiting graduate student. Here he became interested in X inactivation and decided to choose this topic for his postdoc. After having his viva and receiving his PhD degree, Andrea joined the Brockdorff lab later that year. His project was to study the epigenetics of X chromosome inactivation, focusing on understanding how Xist mediates gene silencing. In particular, he was interested in the interplay between Xist and Polycomb Repressive Complexes. He proved that Xist and PRC2 do not interact directly, moving the balance of the much-debated Xist-mediated PRC2 recruitment model toward an indirect recruitment one. Building on this he set up a genome-wide RNAi screen to identify novel factors involved in X chromosome inactivation and run a set of screens. Based on his pioneering system the Brockdorff lab has identified important candidates from these screens.
At the end of 2013 Andrea decided to move on with his career and returned to Italy. Back home, Andrea joined Prof. Phil Avner’s group at the EMBL Monterotondo in 2014 to study the initiation phase of mouse X inactivation, in particular the role of chromatin remodelers in Xist and Tsix regulation.
Andrea lives in Rome with his wife Asia and his dog Cesar.
Biochemistry; molecular genetics; epigenetics
Alain Chapel, PhD, scientific investigator at the Institute of Radioprotection and Nuclear Safety (IRSN), in the Laboratory of Radiopathology and Experimental Therapies. For 20 years, he has been developing gene and cell therapy using non-human primates and immune-tolerant mice and rats to protect against the side effects of radiation. He has developed representative experimental models of SAI to investigate the effect of radiation on both radiosensitive hematopoietic cells and their bone marrow microenvironment. He collaborates with clinicians to develop new strategies for treatment of patients after radiation accidents or radiotherapy overexposures. In compassional trials, he has participated in the first establishment of proof of concept of the therapeutic efficacy of Mesenchymal stem cells (MSCs) for the treatment of hematopoietic deficit, radiodermatitis and over dosages of radiotherapy. In collaboration with Saint-Antoine Hospital (Paris, France), he has contributed to the first reported correction of deficient hematopoiesis in patients (graft failure and aplastic anemia) thanks to intravenous injection of MSCs restoring the bone marrow microenvironment, mandatory to sustain hematopoiesis after total body irradiation. Currently his work focuses on the development of radio-induced bone marrow aplasia using human hematopoietic stem cells derived from human IPS. He is a member of various learned national and international societies: European Bone Marrow Transplantation Group (EBMT), American Society for Hematology, International Society of Stem Cell Research, Société Francaise de Greffe moelle et de thérapie cellulaire. He is an associate editor of eight international journals: World Journal of Stem Cells, World Journal of Gastrointestinal Surgery, World Journal of Radiology, World Research Journal of Gene Therapy, The Open Gene Therapy Journal, Research Journal of Developmental Biology, Journal of Toxicology and Health and Journal of Clinical Rehabilitative Tissue Engineering Research. He has participated in the scientific organization of international conferences: European Group for Blood and Marrow Transplantation (EBMT Paris 2011) and World Biotechnology Congress (Boston, USA, 2013).
Gene and cell therapy
Dr. Jin-Tang Dong received his PhD degree from the Peking Union Medical College and the Chinese Academy of Medical Sciences in 1989. After working as an Assistant Investigator at the same institution for a year, he completed postdoctoral training in Molecular Cancer Biology and Prostate Cancer at the National Institutes of Health (1990-1994) and the Johns Hopkins University School of Medicine (1994-1996). He started his faculty appointment as an Assistant Professor of Pathology, Biochemistry and Molecular Genetics at the University of Virginia in 1996, and joined the faculty of Emory University School of Medicine as an Associate Professor in 2002. He became a full professor in 2007. Dr. Dong received an NIH Director’s award, and is a Georgia Cancer Coalition Distinguished Cancer Scholar. His research interest has been in the molecular pathogenesis of human cancer, with a focus on the identification of novel tumor suppressors and the discovery of novel molecular pathways.
Molecular pathogenesis of human cancer, with a focus on the identification of novel tumor suppressors and the discovery of novel molecular pathways
Dr. Giulia De Falco is a Lecturer in Cellular Pathology and Molecular Microbiology at Queen Mary University of London, UK. Her main research interests have been focusing on the association between infectious agentsand malignant transformation and on the identification of novel genetic alterations in cancer utilizing high-throughput technologies. She is a specialist in Medical Genetics and has a PhD in Molecular Pathology. Dr. De Falco is a fellow of the UK Higher Education Academy and a member of the European Society of Pathology. Dr. De Falco has published over 100 peer-reviewed papers covering cancer, infectious and genetic diseases, and microRNAs. She serves as a reviewer of a number of international medical journals.
Haematopathology; gene and microrna expression profiles; molecular mechanisms of virus-induced malignant transformation
Dr Pascale V Guillot, B.Sc., M.Sc., Ph.D., is a stem cell biologist and the Head of the Cellular Reprogramming and Perinatal Therapy group at University College London, London, UK. The research team of PV Guillot is focused on understanding the biology, therapeutic potential and mechanistic properties of mesenchymal stem cells (MSCs) as well as MSCs derived from induced pluripotent stem cells (iMSC) in models of inflammatory pathologies. PV Guillot obtained a PhD in Paris working on the Y chromosome, and started her scientific career with Dr Mary Lyon at the Harwell Medical Research Council in the UK, before pursuing her research on gene regulation at Harvard Medical School, Boston MA, USA. Back in the UK, her team established that human fetal MSC can be used as countermeasure to bone loss and they are now studying the mechanistic properties of human fetal stem cells. At the same time, they have successfully produced the first chemically-induced pluripotent stem cells from human somatic cells, and they are now delineating the pathways involved into the reactivation of endogenous pluripotent genes.
Therapeutic potential and mechanistic properties of human fetal stem cells; induced pluripotent stem cells
Prof. Ishmael, the director of Basic Science Research of Pennsylvania State University College of Medicine, obtained MD and PhD degree from Pennsylvania State University College of Medicine. Prof. Ishmael is the member of American Health Council, Association of Biochemistry and Molecular Biology, and American Academy of Allergy. He also serves as the Associate Editor of American Journal of Clinical and Experimental Immunology since 2012. His main research interests are the role of reactive oxygen species in the inflammatory response, microRNAs as biomarkers in the diagnosis and pathogenesis of allergic disease, and diagnosis of drug allergy by in vitro methods.
Prof Ishmael has published more than 80 publications in the field of allergy and immunology (including original articles, reviews, abstracts, etc.).
Dr. Kone is a tenured professor and graduate faculty member at the University of Texas-Houston. He received his A.B. degree from Princeton University, his M.D. degree from University of Florida, and clinical training at Johns Hopkins Hospital and Harvard Medical School. He joined the University of Texas-Houston in 1995 and served as the chairman of internal medicine, then became Dean of the University of Florida College of Medicine, before returning to University of Texas-Houston. He has held multiple leadership, editorial board, and peer review. He investigates transcriptional control of epithelial transport, and has been NIH funded for 30 years.
Nephrology; internal medicine
Dr. Lamb has recognised expertise in human genetics research, particularly in autism and idiopathic inflammatory myopathies. She has Research Council UK, EU, Programme Grant and charity funding, through national and international research collaborations. She has made a sustained contribution to teaching, particularly at postgraduate level. She is Programme Director for the Masters of Research (MRes) in Translational Medicine, Faculty of Biology, Medicine and Health at the University of Manchester, and contributes to the development of Teaching and Learning policies at Faculty level. Her excellence in teaching and learning was recognised recently by award of Senior Fellowship of the Higher Education Academy. She is currently Lead for the Centre for Epidemiology, School of Health Sciences. Other roles include membership of the Athena Swan Self-Assessment Team.
Human genetics research, including idiopathic inflammatory myopathies, autism, myasthenia gravis, inherited retinal diseases and interstitial lung disease
Prof. Tin-Lap Lee is an Associate Professor in the School of Biomedical Sciences, Faculty of Medicine at the Chinese University of Hong Kong. Before joining CUHK in 2011, he was a Staff Scientist at the Laboratory of Clinical Genomics, National Institutes of Child Health and Human Development (NICHD) at National Institutes of Health (NIH) in the United States and Project Coordinator at National Center for Biotechnology Information (NCBI).
Prof. Lee is a Hong Kong native. He obtained his undergraduate degree in molecular biology at the Hong Kong University of Science and Technology in 1997, and went on to obtain his Ph.D. in anatomical and cellular pathology at the Chinese University of Hong Kong. In 2001, he was invited to serve as a Visiting Fellow at National Institute of Deafness and Communication Disorder, National Institutes of Health in 2001 to study the molecular and genome biology of head and neck cancer.
Recognizing that a revolution was beginning in genome biology, he pursued studying bioinformatics at National Institute of Bioinformatics and became a Certified Bioinformatics Specialist in 2002, and continue his new scientific adventure in Laboratory of Clinical Genomics, National Institutes of Child Health and Human Development (NICHD) in 2004 to decode the regulatory mechanisms in developmental biology by using male germ cell and tumor models.
Prof. Lee has made a number of accomplishments in molecular and genome biology. He invented the first non-invasive method to detect epigenetic alterations in gastric cancer patients and led to prestigious Scholar-in-Training Award conferred by American Association for Cancer Research in 2001. He also discovered of p53 and NF-Kappab as the key segregating factors for molecular differentiation of head and neck cancer, which was featured on the cover of Clinical Cancer Research. His achievement in bioinformatics revolutionized dynamic analysis of Serial Analysis of Gene Expression (SAGE) data for revealing novel regulatory targets and mechanisms in male germ cell and gonad development. The work was featured on the cover of Genomics and was recognized by National Institutes of Health by prestigious NIH Merit Award in 2005 and The Fellows Award for Research Excellence in 2006. His research performance has also been recognized by Government Employee Performance Awards. He is the author of 63 publications in peer-reviewed journals with more than 1500 citations, and 70 meeting abstracts in national scientific meetings. He has served as government panel member in the genome science policy study, members in various scientific societies and mentor in undergraduate and post-graduate research programs.
Genomic regulations of non-coding RNAs in stem cell development; germline stem cell biology; nanotoxicology and nanomedicine; system biology modeling and algorithm development
Experienced professional with years of experience emphasizing sales, marketing and business development in the area of life science with profound knowledge in next generation sequence based diagnostic test and application. Successfully opening up the contract research service utilizing next generation sequencing and clinical (non-invasive prenatal diagnosis) market worldwide. Invited Professional of the Macau Special Administrative Region and Co-founder of a Hong Kong based Biotechnology Company-GroKen Bioscience Ltd.
Dr. Kenneth Kam was the Vice President of BGI which is responsible for overseeing and managing BGI-America, BGI-Europe, BGI-Asia Pacific and BGI-Hong Kong. During his service in the Hong Kong Government Laboratory, Dr. Kam served as the President of the Hong Kong Government Chemist Association (2006-2007).
Genomics life; sciences DNA; molecular genetics
Recipient of the Croucher Foundation Scholarship, the Sir Edward Youde Scholarship, Jebsen Educational Scholarship, Wong Ching Yee Scholarship, Early Investigator award with 15 publications (SCI journals) and reviewer of The Journal of Pharmacology and Experimental Therapeutics.
Gopeshwar Narayan has completed his Ph.D. from Banaras Hindu University in 1994; and postdoctoral studies from Institute of Human Genetics, Frei University, Berlin, Germany and Columbia University, New York, USA. Currently he is working as Professor in the Department of Molecular and Human Genetics, Banaras Hindu University, Varanasi, India. He has published more than 50 papers in reputed journals in the fields of Animal Genetics, Cancer Genetics and Type 2 Diabetes.
Molecular genetics and cytogenetics
Man-Ho Oh is an Associate Faculty Member who works with Faculty Member Steven Huber to recommend the scientific literature in their field. Their research are focusing on post-translational modification of receptor kinases and plant growth and development to understand brassinosteroids signaling.
Post-translational modification of receptor kinases; plant growth
Dr. Bulent Ozpolat is an Associate Professor at the Department of Experimental Therapeutics at MD Anderson Cancer Center, Houston, TX, USA. He earned his Ph.D. degree in Immunology from The University of Texas-M. D. Anderson Cancer Center-Houston Graduate School of Biomedical Sciences (GSBS) and after gettinghis M.D. degree from The University of DokuzEylul University, Izmir, Turkey. Dr. Ozpolat’scompleted his graduate and post doc training at Departments of Cancer biology and Immunotherapy at MD Anderson. Dr. Ozpolat’sresearch focuses on 1) Identification of genes and non-coding genes (ie microRNAs, LncRNAs) and novel survival pathways, including EF2-Kinase (eEF2K) and autophagy pathways as well as regulation of cell death mechanism (autophagic death and apoptosis) and 2) Development of gene therapies/gene silencing therapies using tumor-targeting nanotherapeuticsin aggressive type of solid tumors (ie, breast, pancreatic and ovarian cancers)and hematological cancers such as leukemia and lymphoma for the delivery of therapeutic cargo includingsiRNA, microRNA small molecule inhibitors, peptides, proteins, cytokinesand anticancer agent. Dr. Ozpolat is a member of Center for Targeted Therapy (CTT) and Non-Coding RNA center and receivedmany research awards in recognition of research excellence. Dr. Ozpolat has published more than 50 papers, 9 book chapter sand 12 review articles in peer-reviewed high impact journals and contributed to textbooks.
Genes and non-coding genes; gene therapies/gene silencing therapies
Tissue-targeted gene delivery (or gene therapy); biomedical polymers (cell adhesion); design and characterization of tissue-specific polymeric molecular imaging; vaccine delivery (inactivated virus, DNA vaccine); gene-activated matrix; gene delivery from implant; thermosensitive hydrogel-mediated local gene transfer
Dr Simon Rabkin is a Professor of Medicine in the Division of Cardiology at the University of British Columbia (UBC). He graduated with an MD from the University of Manitoba. He did post graduate training in Internal Medicine and Cardiology at the University of Toronto, University of Cincinnati and Emory University.
His research interests are in the determinants of cardiovascular disease and its therapy. His research interests and activities have spanned the range from basic science, clinical investigation, clinical trials and epidemiology. He is especially interested in translational medicine in the field of cardiovascular diseases. He has published over 250 scientific papers or book chapters.
Dr Rabkin has received a number of awards for excellence and/or distinguished service from different organizations. He has served on a number of Canadian granting agencies review boards, and Canadian consensus conferences for the development of best practice guidelines for Canadian Physicians. Dr Rabkin is a past President of the Canadian Hypertension Society and was the President of the 23rd Scientific Meeting of the International Society of Hypertension in 2010.
Translation cardiovascular medicine-understanding the translation of genetic data to cardiovascular disease
Dr. Jagannatha Rao was born on 1st June 1956 in India. Dr.Rao had his Masters and Ph.D from Sri Venkateswara University, India. He is currently Director, Institute for Scientific Research and Technology Services (INDICASAT-AIP), Distinguished Scientist, Building 219, Clayton, City of Knowledge, Republic of Panamá, and Member of National Bioethics Committee in Republic Panama. Dr. Rao is also the Adjunct faculty of Biomedical Informatics, University of Texas Health Sciences, and Advisory Board Member of minority scholarship in UTCU- El Paso, USA. His research fields of specializations are: Mechanisms of proteins conformations in neurodegenerative disorders, DNA dynamics in neurodegenerative brain, Development of Alzheimer’s and traumatic brain injury animal models; Aluminium Neurotoxicology; Biomarkers; Neuronutraceuticals. Dr. Rao is on the Editorial board member of 25 journals, guided 20 Ph.D and 8 postdoctoral fellows. He was also on the International review board of Parkinson disease association UK, France Mental health grant program, and Department of Biotechnology, India. He is the Fellow of National Academy of Sciences (India), Linnaean Society (UK), Association of Biotechnology and Pharmacy. He is the guest editor for two special issues of journals on Alzheimer´s disease. He has international collaborations with scientists in USA, UK, Italy, Germany, China, and Japan. He has published 125 papers and 6 book chapters. Professional contributions: Biomarkers in brain disorders: Diet, Nutrition and disease with reference to brain disorders, MRI studies on depression and Alzheimer’s patients. He also involved on blood DNA bank on depression and brain bank on depression, Also involved on drug trials in bipolar disorders, leading a research team on indigenous medicines as alternate therapies for Alzheimer’s and Psoriasis, Pharmacokinetics of molecules and clinical studies of drugs in neuropsychiatry, Trace metals homeostasis in Bipolar and Alzheimer’s and Parkinson disease, Amyloid 42/40, ceruloplasmin, transferring, synuclein in plasma, 8-hydroxy-guanosine as maker in serum and CSF, Strongly Interacting with NIH foundation on Biomarkers. Animal models: Developed animal model to imprint neurodegeneration after traumatic brain injury, Development of non-transgenic environmentally induced Aged Rabbit as Alzheimer’s animal model. Neuronutririon: Nutrition neuroscience is an emerging discipline shedding light on the fact that nutritional factors are intertwined with human cognition, behavior and emotions. Molecular neuroscience: DNA stability in Alzheimer’s, Parkinson and Depression brains, Amyloid and Synuclein aggregation and mathematical modeling of aggregation, A new concept on Protein-DNA complexes in neurodegeneration, Trace metals in neurodegeneration. He was Visiting Scientist at University of Siena, Italy, DBT overseas Associate University of Virginia, USA, Visiting Scientist, University of Virginia, USA, Visiting Scientist, Medical University of South Carolina, USA.
Neurosciences (molecular neurodegenerative pathways)
Vincent M. Riccardi is a clinician, scientist and teacher. He is comfortable and productive at the bedside, in the laboratory and across the podium. His 45-year focus on NF has made him a unique resource for helping some people live with NF and others undertake clinical and research interests in these important disorders. He obtained his bachelor’s degree in zoology at UCLA in 1962, his MD at Georgetown University School of Medicine in 1966 and his MBA at the University of La Verne in 1993. He was an interns and resident at the Health Center Hospitals of the University of Pittsburgh 1966-1968 and Clinical and Research Fellow in Genetics at the Massachusetts General Hospital and Harvard Medical School 1968-1970 and 1972. He was a Major in the United States Army during the Vietnam War. Dr. Riccardi was certified by the American Board of Internal Medicine in 1974 and is a Fellow of the American College of Physicians. He is certified by the American Board of Medical Genetics in Clinical Genetics and Clinical Cytogenetics. He is a Fellow of the American Association for the Advancement of Science and a Fellow of the American College of Medical Genetics. In June 2008, he received the Von Recklinghausen Award. In March 2012 he presented his thesis on the Origin of Life at the American College of Medical Genetics. In October 2012 he was appointed to the External Advisory Board of the Neurofibroma Treatment Acceleration Program. He is also the Mentor for the NTAP Francis S. Collins Scholar Mentorship. He has been a long-standing member of the U.S.A. Department of Defense Neurofibromatosis Research Program Second-Tier Review and Vision-Setting Panel.
Clinical cytogenetics and clinical genetics
Dr. Bidyut Roy is currently working as a professor at Human Genetics Unit, Indian Statistical Institute. He published various articles in international journals.
Genomics of marker development of oral cancer; metabolic gene polymorphism; DNA repair gene; polymorphism; molecular genetic epidemiology; rare genetic disease such as Birt-Hogg-Dube syndrome; susceptibility genes in isoniazid induced hepatotoxicity
Joseph I. Shapiro, M.D. became dean of the Marshall University Joan C. Edwards School of Medicine in July 2012. Dr. Shapiro is a nephrologist with more than 30 years of clinical, teaching and research experience. Previously, he served as associate dean for business development and chair of the department of medicine at the University of Toledo College of Medicine in Toledo, Ohio.
Shapiro’s medical teaching career began at the University of Colorado after completing his fellowship in 1987. He served as an instructor, assistant professor, and associate professor of both medicine and radiology at the University of Colorado until 1997 when he joined the faculty at the University Of Toledo College of Medicine (Medical College of Ohio at Toledo). He served as chair of medicine beginning in 1999, and in 2006, was appointed associate dean for business development at the University of Toledo. He also served as president of the University of Toledo Physicians, the university’s medical practice plan.
In addition to his numerous teaching, clinical and administrative responsibilities at the University of Toledo, Shapiro was the principal investigator or co-investigator on nearly three dozen grant-funded projects totaling more than $30 million and has been involved with the creation of three spin-off companies from that research.
Additionally, Shapiro holds the patents on 14 medical inventions.
He is the author or co-author of more than 100 original research articles, many of them focusing on his chosen specialty, nephrology.
Shapiro is the associate editor for the Journal of the American Heart Association and is on the editorial boards of 13 other journals. He is a member of the American Society of Nephrology, International Society of Nephrology, American College of Physicians, Association of Professors of Medicine and Association of Program Directors in Internal Medicine. He also is active in the American Heart Association, and served as vice chairman of the association’s Kidney in Cardiovascular Disease Council from 2007 to 2008.
He was recognized with the Arnold P. Gold –Healthcare Foundation of New Jersey Humanism in Medicine Award in 2002, and the Mercy Health Partners – Northern Region Endowed Chair of Excellence in Internal Medicine Education in 2003.
A native of Newark, N.J., Shapiro received his medical degree from the University of Medicine and Dentistry of New Jersey in 1980. He earned his Bachelor of Arts degree in mathematics from the University of Pennsylvania. After completing a medical residency in internal medicine at Georgetown University, he trained as a fellow in renal diseases at the University of Colorado. He is board certified in internal medicine and nephrology.
Uremic cardiomyopathy; renal failure; hyponatremia; acid-base; energy metabolism
Prof. Zhenya Tang, MD, PhD is the Professor of the University of Texas MD Anderson Cancer Center since 2014. He obtained MD degree in Tongji Medical University in 1989 and PhD degree in Albert-Ludwigs University in 1998. He is the member of American Society of Human Genetics, Association of Chinese Geneticists in America, American Cytogenetics Conference, Association for Molecular Pathology, Harris County Medical Society, and Texas Medical Association. He also delivered speeches at many international conferences.
Dr. Valencia has the mission of improving health through research, education and diagnostics (precision medicine). He is a biochemist and molecular geneticist, trained at Carleton University, University of North Carolina-Chapel Hill and Emory University, who has basic and translational research programs in genomics and proteomics. His laboratory studies the biochemical mechanisms of apoptosis through a novelproteomic method called mRNA-display. Moreover, his translational research program, in the area of clinical molecular genetics, addresses the implementation of new molecular diagnostic platforms, including next-generation sequencing, in clinical genetic testing and the identification of novel disease causing genes. Academically, Dr. Valencia has an extensive genomics and proteomics publication record which includes articles in respectable journals, namely, Blood, JCI, PNAS and Nature Protocols. In genomics, he has published several key pioneering articles on the clinical application of next-generation sequencing for genetic diseases and he has published more than 20 articles in the field. These articles have received national and international attention and were featured on GenomeWeb, College of American Pathologists (CAP) newsletter and CAP next generation sequencing standard guidelines. More recently, he implemented whole exome sequencing at a diagnostic molecular genetics laboratory. Notably, the diagnostic yield for exome sequencing was about 30% of all patients tested. Additionally, in 2013 he published one of the first books in the field entitled “Next Generation Sequencing Technologies in Medical Genetics”. He serves as reviewer of many genetics and genomics journals and has been invited to speak at numerous national and international conferences.
Throughout his career, Dr. Valencia, has been decorated with numerous academic awards from Carleton University, Ottawa Life Science, Canadian Federation of Biological Societies, Natural Sciences and Engineering Research Council of Canada and the South Eastern Genetics Group. He is a member of many professional societies including the Association for Molecular Pathology (AMP) and the American Society of Human Genetics (ASHG).
Proteomics; apoptosis; degradomics; genomics; next-generation sequencing; genetic testing; whole exome and genome sequencing; diagnostics; human genetics
Translation of next generation sequencing technologies to clinical laboratories.
Prof. Alberto Verrotti was born in Pescara, Italy, in June 13, 1959 and he graduated in Medicine in 1983; he specialized in Pediatrics and in Neurology. Actually, he is Associate Professor of Paediatrics, University of Perugia and Director, Department of Pediatrics, University of Perugia, Italy. His Main Research Interests are: Clinical trials with new antiepileptic drugs, Endocrine consequences of antiepileptic drugs, Preclinical markers of pharmacoresistance in epilepsy, Oxidative stress and metabolic disturbances in epilepsy, Cognitive impairment in epilepsy and Pediatric aspects of Headache. He has been speaker at numerous International and National Congresses.
Clinical trials with new antiepileptic drugs; endocrine consequences of antiepileptic drugs; preclinical markers of pharmacoresistance in epilepsy; oxidative stress and metabolic disturbances in epilepsy; cognitive impairment in epilepsy; headache
Author of 465 papers in International Ranked Journals (Impact Factor: 870, 381).
E Robert Wassman is the Chief Medical Officer of Lineagen, Inc., USA. He has driven the translation and delivery of cutting-edge diagnostic technologies to clinical service for over 30 years. He has held numerous executive positions in the field of genetic testing, Co-Founded Good Start Genetics and was CMO there and at Genzyme Genetics, Rosetta Genomics, Generation Health, Helicos Biosciences, Celula and Alfigen. He is a graduate of Yale University and Albany Medical College and board certified in Pediatrics and Medical Genetics.
Translation and delivery of cutting-edge diagnostic technologies to clinical service
Molecular phylogenetics; molecular coevolution; molecular adaptation in extreme environments
Prof. Hong Xue obtained her M.D. from the Shanghai Second Military Medical University in 1983, Ph.D. from the Institute of medical Sciences, University of Toronto in 1992, and carried out postdoctoral studies at the Department of Genetics, University of Glasgow before joining the Department of Biochemistry, Hong Kong University of Science and Technology in 1995. Currently, she is a Professor of Life Science and the Director of Applied Genomics Center at the Hong Kong University of Science and Technology.
Neural receptor structures and functions; bioinformatics and evolution
Dr. Zhai’s research is concentrated on population-based genetic epidemiological studies. He is interested in applying genomics and metabolomics approaches to identify novel genetic and metabolic markers for osteoarthritis, which can be used to predict disease risk and help better understand the pathogenesis of osteoarthritis. He is also interested in unraveling genetic structure of isolated populations such as the Newfoundland & Labrador population using genome-wide genotype data, and facilitating the efficiency of genetic mapping using this population. In collaboration with other researchers, he applies epigenomics and metabolomics approaches to other complex traits including diabetes, obesity, colorectal cancer, and ankylosing spondylitis.
Pathogenesis and etiology of osteoarthritis; population genetic structure of Newfoundland & Labrador; metabolomics and genomics of complex traits
Between 1984-1987 he was a internal student/ collaboration Fellow in the Department of Genetics at the University of Granada (Spain), where he got his degree in Biological Sciences (1986). After a brief stay in the Agricultural Statistics Service of the Provincial Delegation of Agriculture and Fisheries of the "Junta de Andalucía" in Granada (1986-1987). He started doing his PhD at the "Estación Experimental del Zaidín" (EEZ-CSIC), under the direction of Dr. Maria Isabel Rodríguez García, funded by a FPU / MEC scholarship. During this period he took several predoctoral stays at the University of Reading (UK), the Institut Jacques Monod (Paris) and the Université Livre de Bruxelles. He obtained a doctoral degree in Biological Sciences from the University of Granada in 1991, and after a year of postgraduate at the Estación Experimental del Zaidín, he started a postdoctoral stay at the Department of Plant Sciences, University of Oxford (UK) in the frame of a contract Programme "Human Capital and Mobility of Researchers" of the European Commission, and afterwards with a postdoctoral Fellowship of the PFPI/MEC Subprogram for improvement of Doctors and Technologists abroad. At the Department of Plant Sciences, he worked under the supervision of Prof. Hugh Dickinson until my return to the EEZ in 1996, thanks to a "return" agreement of the "Training and mobility of Researchers" program, also from the European Commission. Between 1997 and 1999, he continued working as a researcher hired in the frame of a research project with Dr. Rodríguez-García until being appointed Tenured Scientist of the Spanish Council for Scientific Research (CSIC) first on an interim basis (1999-2000), which was later consolidated in 2000. He is currently a Research Scientist of the CSIC at the EEZ (2009-) and Head of the Plant Reproductive Biology group from 2012 to the present. He has been the Head of the Confocal and Transmission Electron Microscopy (CTEM) of the EEZ (2010-2014) and Head of the Department of Biochemistry, Cellular and Molecular Biology of Plants (2011-2014). Currently he is a member of the Scientific Committee of the EEZ-CSIC institute.
Analysis of gene expression in the anthers and the ginoecium of the olive and other plants of agronomical interest; characterization of olive allergens and its clinical use; use of molecular markers to track olive cultivars and olive oils; agricultural and food characterization of protein components in the olive seed and olive oil; characterization of the response of the immune system to olive functional foods and allergens
Dr. Khurram Bashir obtained his PhD from The University of Tokyo Japan in 2007. He has a good experience of Plant molecular biology. He has enjoyed prestigious fellowships like JSPS and RIKEN foreign postdoc program. His main research interests are elucidating the molecular response to different abiotic stresses such as mineral deficiency, high temperature and drought stress.
Metal uptake and distribution; heat stress; drought stress; interaction of different abiotic stresses
Vincenzo Belcastro, MD, PhD was born in Reggio Calabria, Italy, in May 28, 1976 and he graduated in Medicine in 2002; he specialized in Neurology. Actually, he works as neurologist at S. Anna Hospital - Como , Italy. His Main Research Interests are: Clinical trials with new antiepileptic drugs, epilepsy and headache. Actually he is the segretary of the Italian Society of Paediatric Neurology.
Clinical trials with new antiepileptic drugs; epileptic syndromes; EEG; paediatric headache
Author of 110 papers in International Ranked Journals.
Isabelle Cleynen graduated with greatest distinction as Master in biomedical sciences at KU Leuven, Belgium, in 2003. In 2007 she obtained her PhD, entitled “Regulation and function of the ‘High Mobility Group’ HMGA proteins during tumor development”, as a Fellow of the Research Foundation Flanders (FWO). From 2007-2015 she was a postdoctoral researcher at the IBD research lab in Leuven, funded by the FWO. Part of her postdoc (2012-2013) was done at the Wellcome Trust Sanger Institute in Cambridge, UK, with Jeffrey Barrett in the Medical Genomics research group. Since 2015 she is appointed assistant professor (tenure track) at KU Leuven (Department of Human Genetics).
Her scientific work has mostly focused on genetics of IBD, and on the functional relevance of the genetic variants in IBD (eg link with expression and function of the respective genes) and has thus far resulted in >45 original research articles in international peer-reviewed journals including Lancet, Nature, Annals of Internal Medicine, Gastroenterology, Gut (current h-index is 18). She presented her research at different (inter-)national conferences. She is a reviewer for several congresses (ECCO, ESHG) and journals (Gut, PLoS One, Nature Reviews Gastroenterology and Hepatology, Inflammatory Bowel Disease, Journal of Crohn’s and Colitis, American Journal of Gastroenterology, Disease Markers, European Journal of Human Genetics). She is also a reviewer for different grant institutions (Wellcome Trust Centre UK, ECCO Fellowships and Grants applications, Canadian Institutes of Health Research (CIHR), Sparks Children’s medical research, Fondation pour la Recherche Médicale FRM).
During her research career, Isabelle Cleynen obtained several research grants amongst which from FWO (Krediet aan Navorsers, 2014), the European Crohn’s and Colitis organization (ECCO, 2013), and the Vlaamse Vereniging Gastroenterologie (VVGE, 2015). She won a Certificate of Recognition as an early stage investigator at Digestive Disease Week (DDW, US) 2015, the National Scholar Award (NSA) at the United European Gastroenterology Week (UEGW, 2010), and the prize for best abstract at the First and Second national cross-disciplinary scientific symposium on Immune Mediated Inflammatory Diseases (2010, 2011), and at the Belgian Society of Human Genetics Meeting (2012). She won the IBD Prize for the Joint Meeting of the Belgian Week of Gastroenterology (2010).
Isabelle Cleynen is elected Chair of the Y-ECCO (young ECCO) committee, and initiated and co- organized the basic science workshop at the ECCO conference since 2015. Since 2017, she is a Member of the UEG Research Board, being nominated by ECCO. She also is a member of the Biobank Board of University Hospitals Leuven, and an active member of the International IBD Genetics Consortium (IIBDGC).
Genetics of inflammatory bowel disease, and functional and clinical relevance of the genetic variants in IBD
Cardiovascular genetics; coronary intervention for all spectrum of acuity (STEMI, NSTE-ACS, UA etc); complex coronary intervention including atherectomy (rotational, orbital or laser atherectomy); percutaneous hemodynamic support with Impella and IABP intracoronary imagines (Optic coherence tomography, intravascular ultrasound); intracoronary hemodynamic assessment; endomyocardial biopsy and management of cardiac allograft vasculopathy; consultative cardiology; geriatric cardiology
Dr. Han has expertise in transposable element-related genomic instability and genetic variation. His laboratory is focusing on the identification and characterization of transposable element (i.e., retrotransposon) involved in genomic instability. Currently using Next Generation Sequencing (NGS) technique, he investigates that transcriptional activity of the retrotransposons can be specifically controlled by the host and may play unrecognized roles in regeneration in animal models and/or patients with lesions in the central/peripheral nervous and musculoskeletal system. In addition, he has been the director of DKU-Theragene institute for NGS analysis (DTiNa) since 2012. He supports various NGS researches including RNA-sequencing, exome sequencing, and epigenome sequencing. DTiNa supports NGS education and experiments for researchers in local biomedical industries and institutes. His bioinformatic expertise is important for basic approaches in transitional biomedical research.
Genetic conflict between host and retroviral genes; mobile element mediated genomic instability; comparative genomics and population genetics; primate genome evolution; forensic genetics; molecular phylogenetic analysis
Award of Excellent Scientists (given to 10 people) in Korea, 2007.
William H. Gates Award for Teaching Excellence, Louisiana State University, 2006.
ASM Travel Grant, Mobile DNA Conference, 2006.
Vice Chancellor’s Graduate Enhancement, Louisiana State University, 2003-2006.
Prof. Liu is interested in applying statistical methods to gene mapping of monogenic and complex human traits/disorders. Currently, her group is working on the following projects:
1)gene mapping for autism-related quantitative traits using identity-by-descent mapping methods to prioritize gene locations for sequencing data analyses;
2)Gene mapping for autism using twins and genome-wide DNA methylation and RNA seq data;
3)Relationships between autiam and “non-genetic” risk factors (e.g. Parental ages, prenatal and perinatal complications, etc.);
4)Chorioncity and genome wode DNA methylation profiles in newborn twins.
Complex trait genetics; gene regulation and expression; genetic mapping; autism
2009-present; Reader, University of Aberdeen.
2006-2009; Senior Lecturer, University of Aberdeen.
2001-2006; Lecturer, University of Aberdeen.
1997-2001;Postdoc. University of Edinburgh Vet School.
1992-1997;Postdoc. MRC Human Genetics Unit, Edinburgh.
1992-Manchester University, Ph.D. in Molecular and Cellular Biology.
1989-University of Strathclyde BSc.(Hons)in Cell Biology.
Gene regulation; molecular genomics; CRISPR genome editing; epigenetics; neuroscience; regulatory variation and epigenetics
He is the Director of the Laboratory of Neurogenetics of the European Center for Brain Research, CERC-IRCCS Santa Lucia, in Rome, Italy, and Associate Professor of Human Genetics at the Department of Surgical and Biomedical Sciences, University of Perugia. He graduated in Medicine and got Board certification in Neurology from the University of Perugia and was awarded the title of Doctor of Philosophy in Neuroscience at the University of Rome "Tor Vergata". He did his post-doc in Canada at the University of Toronto, and since 2001 he returned to Italy. Dr. Orlacchio has expertise in the application of advanced molecular genetic techniques for understanding the pathogenesis of Hereditary Spastic Paraplegia, Alzheimer's disease, Amyotrophic Lateral Sclerosis, Charcot-Marie-Tooth disease and other neurodegenerative diseases and use of that knowledge for clinical problems affecting patients with these diseases.
He has received numerous awards and honors at national and international level, including the European Neurological Society Award, the "San Valentino d'Oro", and the honor of the Chamber of Commerce of Perugia.
Cardiovascular associated genes
Professor Shengying Qin is the director of Personalized Medicine Research Center at Bio-X Institutes of Shanghai Jiao Tong University. His research work mainly focuses on molecule mechanism study of different response of drugs, environment factors etc. between individuals. Identification of personalized medicine biomarkers for cardiovascular disease, psychiatry disease, cancer, ADR and birth defect. He is the Secretary-general and permanent member of Chinese Pharmacogenomics Society, Deputy Secretary-general of Chinese Personalized Medicine-Precision Medicine Science and Industry Alliance, Deputy Secretary-general of Shanghai Pudong Translational Medicine Alliance.
Pharmacogenomics and personalized medicine; birth defect research and disease; genome study
Building the genetic variant database of drug-response-related genes in the Chinese population, discovering a series of new functional genetic variants such as CYP2D6*75 and its combination, studying the functional mechanism of drug-response-related genetic variants in Chinese population;
Discovering a series of biomarkers of drug efficiency and adverse drug reaction related to psychiatry disease, cardiovascular disease, cancer, studying the genetic mechanism of severe drug-induced liver injury and hypersensitivity in Chinese population as the project manager of the iSAEC in China;
Discovering a series of genetic variants related to individual susceptibility of H7N9 virus and tubercle bacillus and verified the function of the markers in cell and mice models, which provide early warning for disease prevention;
Systematically discovering the genetic variants of birth defect such as kidney and brain malformation based on whole genome level, studying its mechanism by using cell and zebra fish model, developing birth defect detection chip of phenylketonuria (PKU) and glycogen accumulation based on Chinese population.
Salvatore Spicuglia, PhD, is a group leader at the TAGC genomic center in Marseille, France. His work is devoted to the characterization of epigenomes during differentiation of mouse and human T cells and in leukemia. Dr. Spicuglia aims to address how the epigenetic marks are governing the way in which genomic information is organized within the cell and how these phenomena play a role in regulating gene expression and in controlling specific cellular functions during cell differentiation and cancer. His team has set up and developed up-to-date genome-wide investigating approaches, along with state-of-the-art bioinformatics, in order to study epigenetics together with transcriptional regulation in normal developing and transformed T lymphocytes. In the past years, they have explored the dynamics of selected histone modifications and transcription factors during early T cell development in vivo, using ChIP assays coupled to NGS technologies. Their data evidenced a previously unappreciated combinatorial of histone methylations associated to the activity of developmentally regulated enhancers and highlighted an epigenetic signature linked to the regulation of tissue specific gene expression. Furthermore, they have recently developed a high-throughput reporter assay to assess enhancer activity in mammals. He was part of the European Blueprint consortium aiming to characterize the full epigenome of human blood cells. He is member of the editorial board of BMC genomics journal and a faculty member of F1000.
Epigenetic and transcriptional regulation of lymphoid cell differentiation and in leukemia; control of V(D)J recombination by chromatin structure and enhancer elements; high-throughput reporter assays
Sharad K. Verma, PhD, is the Director of Research and Development for the Neurofibromatosis Therapy Acceleration Program (NTAP), and an Assistant Professor in the Department of Neurology, at The Johns Hopkins University School of Medicine. In these roles, Dr. Verma oversees basic science and translational initiatives as they pertain to the discovery and development of therapeutics for the treatment of plexiform and cutaneous neurofibromas. Prior to joining Johns Hopkins University, Dr. Verma was in the pharmaceutical industry for over 14 years first working at Bayer (5 yrs), and later GlaxoSmithKline (9+ years), serving in various R&D leadership roles in the discovery and clinical development of oncology therapeutics. Dr. Verma’s core expertise is in preclinical drug discovery and translational development and early clinical development. Dr. Verma has a BS from the University of California, San Diego (Dept. of Chemistry and Biochemistry, a PhD in Chemistry from the University of California, Irvine, and was an NIH Postdoctoral fellow at the University of California, Berkeley.
Neurofibromatosis; oncology; translational research; preclinical drug discovery and development; early clinical development; epigenetics; immunotherapy; signal transduction; synthetic and medicinal chemistry.
NIH Postdoctoral Fellow (UC Berkeley)
Industry: member of multiple project teams spanning the areas of signal transduction, cancer epigenetics, and immuno-oncology, which delivered a total of 6 clinical development candidates (including one that is now FDA approved, and 4 currently in clinical trials). Led the chemical identification of the first reported on-target small molecule inhibitors of the epigenetic target EZH2 being used as chemical probes, including an agent in clinical trials.
Appointed to School of Medicine Faculty, Johns Hopkins University, and Director R&D Neurofibromatosis Therapy Acceleration Program.
Reviewer for multiple scientific journals, scientific advisor for multiple scientific conferences, and is an NIH study section reviewer.
Dr. Margaret "Peggy" Wallace is a Professor in the Department of Molecular Genetics and Microbiology at the University of Florida College of Medicine, where her faculty career began in 1991. She received her B.S. in Mathematics and Statistics from the Miami University, and Ph.D. in Medical Genetics from Indiana University School of Medicine. Her research involves identifying and characterizing genetic and epigenetic contributors to Mendelian and complex conditions/traits, such as the neurofibromatoses and other tumor syndromes, cardiomyopathy, pain sensitivity, and vitiligo. She is also involved in education of graduate and medical students.
Identifying and characterizing genetic and epigenetic contributors to Mendelian and complex conditions/traits, such as the neurofibromatoses and other tumor syndromes, cardiomyopathy, pain sensitivity, and vitiligo
Han-Gang Yu, an associate professor, begins with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable. A majority of obese individuals die of heart disease, with a significant high rate of sudden cardiac death. The long-term goal of his research program is to identify genetic and molecular mechanisms that cause the lethal arrhythmias in obese population. In collaboration with Dr. Robert Hull, a clinical electrophysiologist with expertise in heart failure in Heart Institute of HSC/WVU, we currently focus on obesity-associated cardiac hypertrophy and long QT interval, both are independent risk predictors of sudden cardiac death, even in the absence of hypertension and diabetes mellitus.
His graduate and postdoctoral training are in the field of cardiac electrophysiology with a focus on the biophysics of ion channels. He discovered the cardiac pacemaker current (If, also called Ih in neurons) encoded by Hyperpolarization-activated, Cyclic Nucleotide modulated (HCN) channels in the adult mammalian ventricles, which formed the basis for later development of biological pacemaker to overcomes the disadvantages of electronic pacemaker.
His research has been supported by Forgarty International Research Collaboration Award from National Institutes of Health, Scientist Development Grant (0030124N), Predoctoral Fellowship (10PRE3530011) and Grant-in-Aid (13GRNT16420018) from American Heart Association and an R01 (HL075023) from National Heart, Lung, Blood Institute to study the molecular and cellular modulation of cardiac pacemaker channel (I(f)/HCN) and its potential role in cardiac pacemaker activity during development and in the pathogenesis of arrhythmias in the primary cardiac pacemaker (sinus node) and in the working ventricle.
Most recently, he has received a pilot grant from NIH/NIGMS CTR program grant to West Virginia for studying gene expression profiles of obese human heart with left ventricular hypertrophy. Wealth of gene expression information has revealed many new hypotheses for potential roles of novel genes during the development of cardiac hypertrophy in a gender- and BMI-dependent manner. He has expertise and experience with skills essential for a successful execution of the proposed research in this grant.
Gene expression profiles of obese human heart
1968-1973 -- Master of Science, Erevan State University, Armenia
1973–1975 -- Research Student, Siberian Branch of the Russian Academy of Sciences, Institute of Cytology and Genetics, Novosibirsk, Russia.
1975–1978-- Researcher, Siberian Branch of the Russian Academy of Sciences, Institute of Cytology and Genetics, Novosibirsk, Russia.
1978-1987 -- Senior Scientist and Postdoctoral Fellow, Siberian Branch of the Russian Academy of Sciences, Institute of Cytology and Genetics, Novosibirsk, Russia.
1987-2009 -- Vice-Director of the Institute of Cytology and Genetics, Head of the Laboratory of Biochemical Genetics of Animals, Siberian Branch of the Russian Academy of Sciences, Novosibirsk, Russia.
2008–present -- Head of the Laboratory of Developmental Epigenetics, Siberian Branch of the Russian Academy of Sciences, Institute of Cytology and Genetics, Novosibirsk, Russia.
2009–present -- Head of the Laboratory of Stem Cell, SB RAS Institute of Chemical Biology and Fundamental Medicine, Novosibirsk, Russia.
2010–present -- Head of the Laboratory of Molecular and Cellular Medicine, E.N.Meshalkin Siberian Biomedical Research Center, Russian Ministry of Public Health, Novosibirsk, Russia.
Stem cell biology, developmental epigenetics, genome editing
The study of mechanisms of imprinted X-chromosome inactivation. Common voles F1 hybrids exhibits primary non-random X inactivation. A phenomenon of the nonrandom X-chromosome inactivation in some common voles (genus Microtus, “arvalis”) F1 hybrids correlates with the presents of heterochromatin block on inactivated X-chromosome. Imprinted X-inactivation in vole occurs in a species-specific manner in two steps. X chromosome inactivation in rodents reveals taxon-specific regulation. Generation of induced pluripotent stem cells (iPSCs) from the hybrids of common voles. Characterization of rat pluripotent cells using the RNA-Seq technique for detailed transcriptome analysis. Two types of facultative heterochromatin described in various mammalian species were revealed on the rat inactive X chromosome. Derivation of patient-specific induced pluripotent stem cells from patient with spinal muscular atrophy, hypertrophic cardiomyopathy, inherited form of Alzheimer's disease, long QT syndrome. Development of CRISPR/Cas9 applications for modeling of hereditary hypothalamic diabetes insipidus, for obtaining of isogenic cell models of Huntington's disease, amyotrophic lateral sclerosis.
She got her Bachelor Degree in Pharmacy from the School of Pharmacy at the University of Panama in 2003. During the period 2004-2005, she participated, as research technician, in research projects at Center of Pharmacognostic Research of Panamanian Flora (CIFLORPAN). In 2005, she was accepted in the PhD Program in Biopharmacy, Pharmacology and Drug Quality at Pharmacy and Pharmaceutical Technology Department from the School of Pharmacy, University of Navarra, Spain; where she received her Doctoral degree in Pharmacy in 2010. In 2010, she joined at INDICASAT AIP as postdoctoral researcher working on the discovery of bioactive molecules from natural products and developing nanoformulation of commercial drug to improve drug bioavailability. Currently at INDICASAT AIP, she supports the design, development, implementation, coordination and supervision of academic and training research programs in collaboration with National and International Institutions. Her research interests include drug discovery from natural products, biopharmaceutical and pharmacokinetic studies of bioactive compounds from natural products or synthetic compounds (new and/or commercial product) and the design, characterization and evaluation of new drug delivery systems.
Drug discovery; biopharmaceutics and pharmacokinetic studies; new drug delivery systems
Dr. Mauro was member of ANCT in Rome chemists pharmacists Italian association and regional responsible for SINAFO hosp. pharmacists organizarion (EMILIA ROMAGNA). Dr. Mauro was registered as pharmacists in professional order Piacenza Visiting professor at Saint George School Italy (pharmacology) form 2016. Dr. Mauro has the objective: pharmaceutical care in medical team and involved in clinical pharmacy antidothes stokes management medicinal gas quality control as hospital pharmacist.
Biochemistry; toxicology; blood bank; haematology; microbiology
Prof. Tartaglia is a ICREA Research Professor in the department of Life and Medical Sciences at Centre for Genomic Regulation of University Pompeu Fabra. He got the PhD degree in 2006 from University of Zurich. He also worked for some famous journals, such as Frontiers in Molecular Biosciences; PeerJ; and Current Updates in Bioinformatics.
Bioinformatics and genomics